Current Application of Nanoparticle Drug Delivery Systems to the Treatment of Anaplastic Thyroid Carcinomas.
anaplastic thyroid carcinomas
anti-cancer treatment
nanomaterials
nanomedicine
nanoparticle
Journal
International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
07
2023
accepted:
18
10
2023
medline:
1
11
2023
pubmed:
31
10
2023
entrez:
31
10
2023
Statut:
epublish
Résumé
Anaplastic thyroid carcinomas (ATCs) are a rare subtype of thyroid cancers with a low incidence but extremely high invasiveness and fatality. The treatment of ATCs is very challenging, and currently, a comprehensive individualized therapeutic strategy involving surgery, radiotherapy (RT), chemotherapy, BRAF/MEK inhibitors (BRAFi/MEKi) and immunotherapy is preferred. For ATC patients in stage IVA/IVB, a surgery-based comprehensive strategy may provide survival benefits. Unfortunately, ATC patients in IVC stage barely get benefits from the current treatment. Recently, nanoparticle delivery of siRNAs, targeted drugs, cytotoxic drugs, photosensitizers and other agents is considered as a promising anti-cancer treatment. Nanoparticle drug delivery systems have been mainly explored in the treatment of differentiated thyroid cancer (DTC). With the rapid development of drug delivery techniques and nanomaterials, using hybrid nanoparticles as the drug carrier to deliver siRNAs, targeted drugs, immune drugs, chemotherapy drugs and phototherapy drugs to ATC patients have become a hot research field. This review aims to describe latest findings of nanoparticle drug delivery systems in the treatment of ATCs, thus providing references for the further analyses.
Identifiants
pubmed: 37904863
doi: 10.2147/IJN.S429629
pii: 429629
pmc: PMC10613415
doi:
Substances chimiques
Nanoparticle Drug Delivery System
0
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
6037-6058Informations de copyright
© 2023 Wang and Zhang.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Int J Nanomedicine. 2013;8:1293-306
pubmed: 23569377
Cancers (Basel). 2020 Feb 21;12(2):
pubmed: 32098194
Clin Cancer Res. 2011 Apr 15;17(8):2281-91
pubmed: 21220477
Cancers (Basel). 2021 Mar 12;13(6):
pubmed: 33808984
Mol Cancer Ther. 2018 Jun;17(6):1187-1195
pubmed: 29563163
Lasers Surg Med. 2012 Dec;44(10):840-9
pubmed: 23143780
Photodiagnosis Photodyn Ther. 2018 Dec;24:15-21
pubmed: 30118906
Mol Ther. 2020 Jan 8;28(1):75-88
pubmed: 31672285
Dokl Biochem Biophys. 2019 Mar;485(1):150-152
pubmed: 31201638
Mol Cell Endocrinol. 2017 Jun 15;448:34-40
pubmed: 28288903
Cancer Res. 2013 Apr 15;73(8):2412-7
pubmed: 23423979
Head Neck. 2012 Feb;34(2):230-7
pubmed: 21500309
Front Mol Biosci. 2020 Aug 20;7:193
pubmed: 32974385
Nat Rev Cancer. 2003 May;3(5):380-7
pubmed: 12724736
J Clin Invest. 2016 Mar 1;126(3):1052-66
pubmed: 26878173
Oncotarget. 2015 Dec 29;6(42):44191-206
pubmed: 26496035
World J Surg. 2012 Jun;36(6):1247-54
pubmed: 22311136
Nutr Cancer. 2010;62(1):1-20
pubmed: 20043255
Onco Targets Ther. 2018 Mar 09;11:1345-1352
pubmed: 29563812
J Photochem Photobiol B. 2019 Aug;197:111534
pubmed: 31279897
Nanomedicine (Lond). 2015;10(13):1993-5
pubmed: 26096565
Clin Cancer Res. 2015 Jul 1;21(13):2898-904
pubmed: 26133775
Cancers (Basel). 2022 Feb 24;14(5):
pubmed: 35267472
Eur J Endocrinol. 2016 Dec;175(6):521-529
pubmed: 27926471
IUBMB Life. 2022 May;74(5):433-445
pubmed: 35112451
Toxicol In Vitro. 2007 Aug;21(5):887-91
pubmed: 17391909
Nanoscale. 2021 Sep 17;13(35):15021-15030
pubmed: 34533142
World J Otorhinolaryngol Head Neck Surg. 2018 Aug 11;5(1):34-40
pubmed: 30775700
J Natl Cancer Inst. 2018 Sep 1;110(9):1019-1029
pubmed: 29481652
Nat Rev Cancer. 2013 Mar;13(3):184-99
pubmed: 23429735
Int J Nanomedicine. 2017 Aug 21;12:5993-6003
pubmed: 28860762
Leukemia. 2002 Sep;16(9):1791-8
pubmed: 12200695
Oncogene. 2013 Aug 22;32(34):3923-32
pubmed: 23246968
Biomaterials. 2015 Jul;57:41-9
pubmed: 25913249
J Natl Cancer Inst. 2000 Oct 4;92(19):1564-72
pubmed: 11018092
Nanoscale. 2020 Dec 21;12(47):24206-24213
pubmed: 33289738
Thyroid. 2013 Nov;23(11):1470-8
pubmed: 23488941
Curr Top Med Chem. 2009;9(15):1479-92
pubmed: 19860730
Nanoscale. 2016 Jul 7;8(25):12524-30
pubmed: 26822539
Life Sci. 2019 Oct 1;234:116781
pubmed: 31430455
PLoS One. 2013;8(1):e54302
pubmed: 23372702
Eur J Endocrinol. 2020 Aug;183(2):203-209
pubmed: 32460234
Gan To Kagaku Ryoho. 2005 Jul;32(7):935-40
pubmed: 16044950
Endocr Relat Cancer. 2021 Jan;28(1):15-26
pubmed: 33112817
JAMA Oncol. 2020 Sep 1;6(9):1397-1404
pubmed: 32761153
Macromol Biosci. 2023 Jan;23(1):e2200262
pubmed: 36259557
World J Gastroenterol. 2011 Feb 21;17(7):932-7
pubmed: 21412503
Bioengineered. 2021 Dec;12(1):6572-6578
pubmed: 34506254
Acta Pharmacol Sin. 2017 Jun;38(6):764-781
pubmed: 28552910
J Clin Endocrinol Metab. 2003 Aug;88(8):3531-8
pubmed: 12915632
Curr Opin Chem Biol. 2010 Jun;14(3):412-20
pubmed: 20409745
Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1137-43
pubmed: 15519785
Mater Sci Eng C Mater Biol Appl. 2017 Dec 1;81:127-132
pubmed: 28887955
Br J Cancer. 2021 Aug;125(3):390-401
pubmed: 34088989
Int Urol Nephrol. 2009;41(2):251-7
pubmed: 18777199
Int J Nanomedicine. 2018 Dec 06;13:8339-8354
pubmed: 30584304
Mod Pathol. 2020 Aug;33(8):1595-1605
pubmed: 32203095
Adv Drug Deliv Rev. 2018 May;130:17-38
pubmed: 30009886
Thyroid. 2017 Dec;27(12):1534-1543
pubmed: 29032724
Int J Mol Sci. 2018 May 13;19(5):
pubmed: 29757257
Int J Pharm. 2004 Apr 15;274(1-2):167-83
pubmed: 15072793
Carcinogenesis. 2014 Jul;35(7):1564-72
pubmed: 24583924
Oncologist. 2015 Jun;20(6):660-73
pubmed: 26001391
J Clin Oncol. 2020 Aug 10;38(23):2620-2627
pubmed: 32364844
Int J Nanomedicine. 2006;1(2):115-6
pubmed: 17722527
N Engl J Med. 2016 Sep 15;375(11):1054-67
pubmed: 27626519
Head Neck. 2017 Jul;39(7):1291-1295
pubmed: 28452157
Adv Healthc Mater. 2021 Feb;10(3):e2001029
pubmed: 33326188
Thyroid. 2020 Sep;30(9):1288-1296
pubmed: 32216548
Cancer Epidemiol. 2018 Apr;53:65-71
pubmed: 29414634
Nat Commun. 2019 Jun 24;10(1):2764
pubmed: 31235699
Adv Sci (Weinh). 2023 Jan;10(3):e2204334
pubmed: 36453580
Int J Cancer. 2010 May 1;126(9):2067-78
pubmed: 19711346
Clin Transl Med. 2017 Dec 11;6(1):44
pubmed: 29230567
Chem Rev. 2014 May 14;114(9):5057-115
pubmed: 24517847
Macromol Biosci. 2012 Sep;12(9):1265-71
pubmed: 22887783
Patient Prefer Adherence. 2020 Jun 03;14:927-937
pubmed: 32581519
Endocr Relat Cancer. 2015 Oct;22(5):759-75
pubmed: 26206776
Biomater Sci. 2021 Feb 23;9(4):1313-1324
pubmed: 33350399
Thyroid. 2020 Oct;30(10):1505-1517
pubmed: 32284020
Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7750-5
pubmed: 27342857
Front Mol Biosci. 2020 Dec 03;7:610084
pubmed: 33344508
Cancer Treat Rev. 2009 Aug;35(5):403-8
pubmed: 19369008
Nanotheranostics. 2021 Jan 1;5(2):143-154
pubmed: 33457193
J Oncol. 2020 Jul 13;2020:5194780
pubmed: 32765604
Cancer Manag Res. 2020 Dec 24;12:13369-13379
pubmed: 33380841
Sci Technol Adv Mater. 2021 Feb 1;21(1):856-866
pubmed: 33551680
Nanoscale Res Lett. 2019 Mar 14;14(1):96
pubmed: 30874973
Annu Rev Physiol. 2017 Feb 10;79:261-289
pubmed: 28192058
Br J Cancer. 2005 Oct 3;93(7):781-92
pubmed: 16175187
Exp Ther Med. 2016 Dec;12(6):3735-3741
pubmed: 28105105
Int Immunopharmacol. 2018 Nov;64:333-339
pubmed: 30243069
Colloids Surf B Biointerfaces. 2017 Feb 1;150:408-416
pubmed: 27829536
Recent Pat Anticancer Drug Discov. 2014 Jan;9(1):1-20
pubmed: 23312026
PLoS One. 2011 May 06;6(5):e19121
pubmed: 21573151
APL Bioeng. 2019 Mar 26;3(1):011502
pubmed: 31069332
Histol Histopathol. 2012 Feb;27(2):217-24
pubmed: 22207556
Nat Rev Endocrinol. 2017 Nov;13(11):644-660
pubmed: 28707679
Cells. 2018 Dec 11;7(12):
pubmed: 30544959
Nature. 2006 Mar 23;440(7083):463-9
pubmed: 16554806
Drug Deliv. 2017 Nov;24(1):670-680
pubmed: 28368209
Vascul Pharmacol. 2017 Mar;90:8-18
pubmed: 28082117
Semin Radiat Oncol. 2012 Jul;22(3):254-62
pubmed: 22687950
Acta Neuropathol. 2017 Oct;134(4):521-535
pubmed: 28821944
J Nutr Biochem. 2002 Jul;13(7):421-426
pubmed: 12121829
Nano Converg. 2019 Jul 15;6(1):23
pubmed: 31304563
Acta Biomater. 2020 Jan 15;102:367-383
pubmed: 31778831
Thyroid. 2021 Mar;31(3):337-386
pubmed: 33728999
J Mater Chem B. 2015 May 21;3(19):4074-4081
pubmed: 32262629
Front Oncol. 2022 Jul 25;12:889284
pubmed: 35957867
Drug Discov Today Technol. 2018 Dec;30:1-2
pubmed: 30553513
ESMO Open. 2020 Mar;5(2):
pubmed: 32220947
Biomaterials. 2022 Jan;280:121312
pubmed: 34896861
Adv Mater. 2013 Jun 18;25(23):3144-76
pubmed: 23681931
Nanoscale. 2018 Dec 13;10(48):22657-22672
pubmed: 30500042
Phytother Res. 2018 Nov;32(11):2164-2190
pubmed: 30088293
Cancer Chemother Pharmacol. 2014 Jul;74(1):211-5
pubmed: 24817602
J Clin Endocrinol Metab. 2012 Jul;97(7):E1139-49
pubmed: 22549934
ACS Nano. 2012 Aug 28;6(8):7489-96
pubmed: 22812694
Oncol Rep. 2020 May;43(5):1491-1502
pubmed: 32323855
Sci Transl Med. 2015 Nov 18;7(314):314ra183
pubmed: 26582898
BMC Cancer. 2004 Sep 13;4:63
pubmed: 15363094
Front Bioeng Biotechnol. 2019 Dec 17;7:415
pubmed: 31921819
Virchows Arch. 2020 Mar;476(3):431-437
pubmed: 31732814
Acta Biomater. 2017 Nov;63:163-180
pubmed: 28923539